<- Go Home
Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Market Cap
$70.7M
Volume
396.4K
Cash and Equivalents
$31.1M
EBITDA
-$90.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$32.41
52 Week Low
$1.25
Dividend
N/A
Price / Book Value
0.88
Price / Earnings
-0.82
Price / Tangible Book Value
0.88
Enterprise Value
-$17.4M
Enterprise Value / EBITDA
0.20
Operating Income
-$90.3M
Return on Equity
82.06%
Return on Assets
-48.67
Cash and Short Term Investments
$88.7M
Debt
$540.0K
Equity
$80.5M
Revenue
N/A
Unlevered FCF
-$46.7M
Sector
Biotechnology
Category
N/A